In GBM clinical trials, TGF-β pathway are targeted by antisens oligonucleotide (trabedersen, NCT004331561) and by small molecules, OKN-007 (NCT03649464) [271], and galunisertib (NCT01582269, NCT01220271). The gene discussed is TGFB1; the disease is glioblastoma.